Brain metastases (BM) affect approximately 30% of patients with cancer.¹ Given the guarded intracranial efficacy of many systemic therapies, BM are routinely managed with local therapies, including brain-directed radiation and neurosurgery.^2,3 Population-based studies of BM have historically been lacking, largely due to uncertainty regarding whether claims can reliably (i) identify BM, (ii) delineate the date of intracranial involvement, and (iii) characterize intracranial management. Although validated approaches now exist to identify BM⁴ and the associated date of diagnosis,⁵ no validated claims-based methods to characterize intracranial management exist. We sought to assess whether claims can accurately identify the receipt and date of brain-directed local therapies among patients with BM.

中文翻译：

---

索赔数据用于描述脑转移患者的颅内治疗。

脑转移（BM）影响大约30％的癌症患者。¹鉴于许多全身疗法的颅内疗效均得到严格保护，因此，BM通常采用局部疗法进行常规治疗，包括脑定向放射和神经外科手术。^2,3历史上一直缺乏以人群为基础的研究，这主要是由于对索赔是否能够可靠地（i）识别BM，（ii）描绘颅内受累日期，以及（iii）表征颅内治疗的不确定性。尽管现在存在用于确定BM ⁴和相关诊断日期的经过验证的方法，⁵不存在经过验证的基于索赔的表征颅内管理的方法。我们试图评估索赔是否可以准确识别BM患者中以脑为导向的局部治疗的日期和日期。